NCT00002800View on ClinicalTrials.gov

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 1996

Primary Completion Date

March 31, 2003

Study Completion Date

March 31, 2003

Conditions

LeukemiaMyelodysplastic SyndromesNeutropenia

Interventions

BIOLOGICAL

filgrastim

BIOLOGICAL

lintuzumab

DRUG

cytarabine

DRUG

etoposide

DRUG

idarubicin

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00002800 - Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter